Old CIC Events
04/11/2021
Tumor-specific pathways of therapy resistance in ALK-rearranged lymphoma
Roberto Chiarle — Harvard Medical School [Boston, USA]
29/10/2021
Defensa de tesis: Evaluación preclínica de mecanismos de resistencia a fármacos inmunomoduladores en mieloma múltiple
Pedro Mogollón Arroyo — Centro de Investigación del Cáncer
28/10/2021
Arginine methylation and ubiquitylation crosstalk controls DNA end resection and homologous recombination repair
María Pilar Sánchez-Bailón — Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch [Berlin, Germany]
21/10/2021
Insights into the biological determinants of clonal evolution and therapeutic vulnerabilities of del(11q) chronic lymphocytic leukemia
Miguel Quijada Álamo — Centro de Investigación del Cáncer, CIC-IBMCC
14/10/2021
Evolutionary dynamics of human cancers
Trevor Graham — Cancer Research UK Barts Centre / Queen Mary University of London
07/10/2021
Targeting RAS-PI3K signaling to re-educate the stroma of RAS mutant lung cancers
Esther Castellano — Centro de Investigación del Cáncer, CIC-IBMCC
01/07/2021
Role of RRAS2 as an oncogenic driver
Laura Clavaín — Centro de Investigación del Cáncer (CIC-IBMCC)
24/06/2021
Control of Actin Polymerization in Cells Through Activation and Inhibition of the Arp2/3 Complex
Roberto Domínguez — Department of Physiology. University of Pennsylvania. Perelman School of Medicine (Philadelphia, USA)
17/06/2021
Role of cytosine-5 methylation of ribosomal RNA in cell cycle control
Judith López Luis — Centro de Investigación del Cáncer (CIC-IBMCC)
15/06/2021
Addressing the true complexity of biology with 10x Genomics single cell and spatial multiomics
Luca Mazzitelli , 10x Genomics — 10x Genomics
10/06/2021
Novel mechanisms controlling KRAS oncogenic output: impact on tumour fitness and cancer vulnerabilities
David Santamaría — University of Bordeaux, France
